DB:LZ1

Stock Analysis Report

Executive Summary

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States.


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Momenta Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LZ1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.7%

LZ1

11.3%

DE Biotechs

7.1%

DE Market


1 Year Return

84.0%

LZ1

-5.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: LZ1 exceeded the German Biotechs industry which returned -5.4% over the past year.

Return vs Market: LZ1 exceeded the German Market which returned -17.5% over the past year.


Shareholder returns

LZ1IndustryMarket
7 Day2.7%11.3%7.1%
30 Day-14.3%-8.0%-20.0%
90 Day26.7%-22.7%-26.1%
1 Year84.0%84.0%-4.9%-5.1%-15.0%-17.5%
3 Year84.0%84.0%17.7%16.4%-18.8%-25.8%
5 Year64.8%64.8%-5.1%-7.5%-17.9%-29.2%

Price Volatility Vs. Market

How volatile is Momenta Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Momenta Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

6.69x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LZ1's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LZ1's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LZ1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: LZ1 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LZ1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LZ1 is overvalued based on its PB Ratio (6.7x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Momenta Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

14.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LZ1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LZ1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LZ1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LZ1's revenue (46.7% per year) is forecast to grow faster than the German market (4.2% per year).

High Growth Revenue: LZ1's revenue (46.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: LZ1 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Momenta Pharmaceuticals performed over the past 5 years?

-27.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LZ1 is currently unprofitable.

Growing Profit Margin: LZ1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LZ1 is unprofitable, and losses have increased over the past 5 years at a rate of -27.8% per year.

Accelerating Growth: Unable to compare LZ1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LZ1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: LZ1 has a negative Return on Equity (-63.82%), as it is currently unprofitable.


Next Steps

Financial Health

How is Momenta Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: LZ1's short term assets ($539.1M) exceed its short term liabilities ($106.1M).

Long Term Liabilities: LZ1's short term assets ($539.1M) exceed its long term liabilities ($57.8M).


Debt to Equity History and Analysis

Debt Level: LZ1 is debt free.

Reducing Debt: LZ1 has not had any debt for past 5 years.


Balance Sheet

Inventory Level: LZ1 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if LZ1's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LZ1 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LZ1 has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of -17.4% each year.


Next Steps

Dividend

What is Momenta Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LZ1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate LZ1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LZ1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LZ1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LZ1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Craig Wheeler (59yo)

13.5s

Tenure

US$4,610,270

Compensation

Mr. Craig A. Wheeler has been the Chief Executive Officer and President of Momenta Pharmaceuticals Inc. since September 12, 2006 and August 22, 2006, respectively. Mr. Wheeler has been an Executive Directo ...


CEO Compensation Analysis

Compensation vs Market: Craig's total compensation ($USD4.61M) is about average for companies of similar size in the German market ($USD3.79M).

Compensation vs Earnings: Craig's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Craig Wheeler
President13.5yrsUS$4.61m0.50% $13.7m
Young Kwon
Chief Financial & Business Officer0.17yrUS$2.37m0.12% $3.3m
Anthony Manning
Chief Scientific Officer1.42yrsUS$2.18m0.011% $307.2k
Santiago Arroyo
Chief Medical Officer & Senior VP of Development2.75yrsUS$2.31m0.024% $655.3k
Scott Storer
Consultant1.42yrsUS$1.98m0.019% $518.2k
Ganesh Kaundinya
Co-Founder & Consultantno dataUS$1.52m0.42% $11.5m
Agnieszka Cieplinska
Principal Accounting Officer0.17yrno datano data
Patricia Eisenhaur
Vice President of Investor Relations & Communications1.17yrsno datano data
Alejandra Carvajal
Chief Legal Officer1.42yrsno data0.0084% $233.4k
Jo-Ann Beltramello
Chief Human Resources & Infrastructure Officerno datano data0.044% $1.2m

1.4yrs

Average Tenure

52yo

Average Age

Experienced Management: LZ1's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Craig Wheeler
President13.5yrsUS$4.61m0.50% $13.7m
Bruce Downey
Chairman1.75yrsUS$284.10k0.028% $784.6k
J. Crout
Member of Regulatory Advisory Boardno datano datano data
Thomas Garvey
Member of Regulatory Advisory Boardno datano datano data
Georges Gemayel
Independent Director4.17yrsUS$268.60k0.012% $339.2k
Steven Gilman
Independent Director3.75yrsUS$266.60k0.0068% $187.6k
Robert Pollock
Member of Regulatory Advisory Boardno datano datano data
Benito Casu
Member of Scientific Advisory Boardno datano datano data
Richard Cooper
Member of Regulatory Advisory Boardno datano datano data
Corey Fishman
Independent Director3.5yrsUS$271.10k0.0088% $242.8k

3.8yrs

Average Tenure

62.5yo

Average Age

Experienced Board: LZ1's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.6%.


Top Shareholders

Company Information

Momenta Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Momenta Pharmaceuticals, Inc.
  • Ticker: LZ1
  • Exchange: DB
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.063b
  • Listing Market Cap: US$2.763b
  • Shares outstanding: 114.76m
  • Website: https://www.momentapharma.com

Number of Employees


Location

  • Momenta Pharmaceuticals, Inc.
  • 301 Binney Street
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MNTANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2004
LZ1DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2004

Biography

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company’s biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/28 20:34
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.